Money Control Place
  • Politics
  • Business
  • Stocks
  • Investing
  • Politics
  • Business
  • Stocks
  • Investing

Money Control Place

Politics

Sanders targets pharma CEOs to testify in Senate, but some see ‘retaliation’ for lawsuit against Biden admin

by January 20, 2024
January 20, 2024
Sanders targets pharma CEOs to testify in Senate, but some see ‘retaliation’ for lawsuit against Biden admin
Read this article for free!
Plus get unlimited access to thousands of articles, videos and more with your free account!
Please enter a valid email address.
By entering your email, you are agreeing to Fox News Terms of Service and Privacy Policy, which includes our Notice of Financial Incentive. To access the content, check your email and follow the instructions provided.

Sen. Bernie Sanders, I-Vt., announced this week he plans to hold a vote on Jan. 31 to subpoena the CEOs of two big Pharma companies for a hearing on drug pricing in front of the Health, Education Labor & Pensions (HELP) Committee after they refused to testify last year.

The subpoenas for Johnson & Johnson CEO Joaquin Duato and Merck CEO Robert Davis would have them testify about why their costs for medicine are ‘substantially higher’ compared to other countries, the announcement said. 

But some executives see the pending subpoenas as a form of retaliation for a court battle over Medicare price negotiations.

‘It is absolutely unacceptable that the CEOs of Johnson & Johnson and Merck have refused an invitation by a majority of members on the HELP Committee to appear before Congress about the outrageously high price of prescription drugs,’ Sanders said. ‘These CEOs may make tens of millions of dollars in compensation. The pharmaceutical companies they run may make billions in profits.’

In November, Sanders requested Duato and Davis for testimonies on drug pricing, but they insisted that a ‘senior pharmaceutical executive best positioned to address and provide Johnson & Johnson’s position regarding the issues’ should instead appear, according to a letter Johnson & Johnson attorney Brian D. Smith sent to Sanders this week in response to the subpoena announcement. 

‘Johnson & Johnson offered to make available for the hearing the senior pharmaceutical executive best positioned to address and provide Johnson & Johnson’s position regarding the issues posed in your invitation letter,’ Smith wrote. ‘Throughout these discussions, Johnson & Johnson has also made clear its concerns with the direction the Committee is taking with the hearing, including the reasons that the company’s chief executive is not the appropriate witness for this hearing. We appreciate the opportunity to reiterate the concerns that we have previously conveyed to your staff over the past three months, and we urge you to consider permitting the Committee to hear from the appropriate executive for these topics.’

The two Pharma companies, alongside others, are currently suing to freeze Medicare drug price negotiation under Biden’s Inflation Reduction Act. Merck Executive Vice President Jennifer Zachary also sent a letter to Sanders this week suggesting the request to have the CEOs testify in front of the Senate panel is a form of ‘retaliation’ for the ongoing lawsuit.

 ‘We appreciate that many Committee members have expressed their disagreement with our lawsuit, and we respect their good-faith views. That said, your public criticisms of the Companies for challenging the IRA and comments regarding hearing witnesses indicate that the invitations to testify have been extended as retaliation for the Companies’ exercise of their constitutional right to seek relief in court,’ Zachary wrote. 

Joe Grogan, who served as a domestic policy advisor to former President Trump, told Fox News Digital in an interview that ‘CEOs are not the subject matter experts in the company who can explain all the different aspects of the pharmaceutical supply chain’ and negotiations with other governments.

‘To put a fine point on it, it’s completely un-American,’ Grogan said. ‘I mean, these companies have every right to avail themselves of the courts, they have every right to sue and to be for him to target these three companies is not a coincidence.’

This post appeared first on FOX NEWS
0
FacebookTwitterGoogle +Pinterest
previous post
A Biotech Stock with a Breakout on the Weekly and a Classic Retracement on the Daily
next post
Americans are feeling optimistic about the economy again, with some exceptions

Related Posts

Senate GOP rallies behind McCarthy’s impeachment inquiry against...

September 14, 2023

Biden admin launches push to expand voter registration...

August 27, 2023

Trump Jr says he’d go to ‘great lengths’...

December 28, 2023

First Republican presidential debate an ‘awesome opportunity’ for...

August 24, 2023

WI GOP won’t make substantive changes to budget,...

June 28, 2023

Republican presidential candidate Ryan Binkley drops out, endorses...

February 28, 2024

Trump said he could end Ukraine war nearly...

February 23, 2024

Biden, White House blame Israel war for forgetting...

February 9, 2024

GOP lawmaker introduces bill requiring age verification technology...

December 22, 2023

Federal appeals court denies Trump request to toss...

January 24, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • Joe Rabil’s Undercut & Rally Pattern: From DROP to POP

    • RRG Alert Tech Vaults to ‘Leading’—Is XLK Signaling a New Rally?

    • Coelacanth Energy

    • Jeffrey Christian: Gold, Silver, PGMs — Short-term Prices and Key Drivers

    • Ericsson, Rogers Launch Canada’s First Underground 5G Network for Smart Mining

    • Crypto Market Recap: Bitcoin Price Stalls as Fed Holds Rates Steady, Circle Shares Jump

    Categories

    • Business (1,259)
    • Investing (2,583)
    • Politics (3,699)
    • Stocks (1,669)
    • Uncategorized (20)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: MoneyControlPlace.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 moneycontrolplace.com | All Rights Reserved